SK bioscience

SK bioscience, a pharmaceutical preparation manufacturer headquartered in South Korea, has reported its carbon emissions for recent years, offering insights into its climate impact.

For the reporting year 2024, SK bioscience reported a total of approximately 58.3 million kg CO2e. This figure is comprised of Scope 1 emissions totalling about 10.4 million kg CO2e and Scope 2 emissions amounting to approximately 15 million kg CO2e. Scope 3 emissions were significantly higher, reaching about 32.9 million kg CO2e. Within Scope 3, purchased goods and services represented the largest portion, at approximately 19.5 million kg CO2e, followed by the end-of-life treatment of sold products at about 7.8 million kg CO2e.

In the preceding year, 2023, the company's total emissions were approximately 40.4 million kg CO2e. This included Scope 1 emissions of about 5.9 million kg CO2e, Scope 2 emissions of approximately 13.8 million kg CO2e, and Scope 3 emissions of around 21.8 million kg CO2e. Purchased goods and services were again the largest contributor to Scope 3, at about 7.1 million kg CO2e, with the end-of-life treatment of sold products at approximately 7.5 million kg CO2e.

For the reporting year 2022, SK bioscience disclosed Scope 1 emissions of approximately 5.2 million kg CO2e and Scope 2 emissions of about 13.3 million kg CO2e, making a combined total of approximately 18.5 million kg CO2e. Scope 3 data was not fully disclosed for this year, with the category of purchased goods and services marked as missing.

In 2021, the company's Scope 1 and 2 emissions totalled approximately 16.9 million kg CO2e. Scope 3 emissions for this year were reported at approximately 153.4 million kg CO2e. Similar to 2022, the category of purchased goods and services within Scope 3 was marked as missing data.

SK bioscience's emissions data is cascaded from SK bioscience Co.,Ltd. For climate initiatives, reduction targets, and SBTi, the data originates from SK Chemicals Co.,Ltd, indicating a corporate family relationship at cascade level 1. While specific reduction targets are not detailed in the provided information, the company's reporting on its emissions across all scopes suggests a commitment to transparency in its environmental performance within the pharmaceutical preparation manufacturing sector.